Fulgent Genetics, Inc.
FLGTNasdaqHealthcare · Services-Medical Laboratories · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $322.7M | $283.5M | $289.2M | $619.0M | $359.4M | $7.8M |
| Operating income | −$91.1M | −$73.9M | −$195.5M | $178.5M | $266.9M | −$1.9M |
| Net income | −$60.5M | −$42.7M | −$167.8M | $143.4M | $200.7M | −$2.0M |
| Total assets | $1.21B | $1.22B | $1.24B | $1.39B | $1.28B | $700.5M |
| Total liabilities | $106.8M | $90.8M | $102.0M | $116.2M | $112.8M | $131.1M |
| Equity | $1.11B | $1.13B | $1.14B | $1.27B | $1.16B | $569.4M |
| EPS (diluted) | — | — | — | — | — | — |
| Shares out. | 30.8M | 29.8M | 29.5M | 30.3M | 28.9M | 21.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −28.2%
- Net margin
- −18.8%
- Return on equity
- −5.4%
- Return on assets
- −5.0%
- Return on capital (ROCE)
- −8.1%
- Liabilities / assets
- 8.8%
- Debt / equity
- 0.10×
- Book value / share
- $36.07
- Revenue growth (YoY)
- 13.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 14.37safe
- Accruals / assets
- 3.4%clean
- Beneish M-Score
- -2.35normal
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 warning● 4 good- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Hsieh MingActivist (13D)May 27, 2026
- Millennium Management LlcPassive (13G)Feb 4, 2026
- Barclays PlcPassive (13G)May 13, 2025
- Blackrock, Inc.Passive (13G)Apr 3, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Xie JianOfficer — President and COO | May 27, 2026 | Sell | 1,201 | $17.60 |
| Kim PaulOfficer — CFO and Treasurer | May 26, 2026 | Tax withholding | 1,168 | $17.67 |
| Gao HanlinOfficer — Chief Scientific Officer | May 27, 2026 | Sell | 945 | $17.60 |
| Hsieh MingOfficer — Chief Executive Officer | May 26, 2026 | Tax withholding | 2,949 | $17.67 |
| Nohaile MichaelDirector | May 14, 2026 | Grant | 5,558 | $0.00 |
| Dong LindaDirector | May 14, 2026 | Grant | 11,117 | $0.00 |
| Groves Regina EDirector | May 14, 2026 | Grant | 11,117 | $0.00 |
| Gao HanlinOfficer — Chief Scientific Officer | Apr 26, 2026 | Tax withholding | 1,645 | $16.31 |
| Xie JianOfficer — President and COO | Apr 26, 2026 | Tax withholding | 4,361 | $16.31 |
| Kim PaulOfficer — CFO and Treasurer | Apr 26, 2026 | Tax withholding | 2,747 | $16.31 |
| Xie JianOfficer — President and COO | Feb 26, 2026 | Tax withholding | 1,140 | $24.76 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 2.7M | 3.9 | +8.7% |
| Apr 30, 2026 | 2.5M | 6.3 | -5.9% |
| Apr 15, 2026 | 2.7M | 5.6 | +7.7% |
| Mar 31, 2026 | 2.5M | 3.3 | +15.5% |
| Mar 13, 2026 | 2.1M | 2.2 | +38.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventMay 21, 2026
- Director / officer change · Shareholder voteMay 14, 2026
- Results of operations · Regulation FD disclosureMay 1, 2026
- Entered a material agreement · Completed an acquisition or disposition · Regulation FD disclosureMar 17, 2026
- Results of operations · Regulation FD disclosureFeb 27, 2026
- Entered a material agreement · Other material eventDec 22, 2025
- Results of operations · Regulation FD disclosureNov 7, 2025
- Other material eventOct 20, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.